Researchers surveyed survivors of early-stage hormone receptor-positive breast cancer who did not receive chemotherapy to assess the symptom burden in this patient population.

The NIH said capping indirect cost payments will save billions of dollars. Universities said it will disrupt vital, life-saving research.

Researchers found that, in patients with stage III NSCLC, treatment with cCRT and an ICI was safe, but treatment with cCRT and 2 ICIs led to “excessive mortality.” ...

Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

Testosterone therapy after prostate cancer surgery does not appear to increase biochemical recurrence (BCR) risk in patients with low-risk disease, investigators report.

Prevalence of preterm birth and low birth weight slightly higher, but no difference seen in prevalence of birth defects.